A comparative study of tellurium metallicum 30C vs placebo in the management of tinea corporis: An open label, prospective, randomized, pilot trial

Abstract

Tinea corporis is a chronic fungal skin infection. While Tellurium Metallicum has been traditionally used in homoeopathy for skin conditions, its efficacy has not been validated in a randomized and controlled setting. This open label, prospective, randomized, placebo controlled pilot trial aimed to evaluate the efficacy of Tellurium Metallicum 30 Centesimal compared to a placebo for managing Tinea corporis. Thirty patients were randomly allocated into two equal groups of fifteen to receive either the homoeopathic medicine or a placebo. The primary outcome assessed was the change in the Dermatology Life Quality Index score over a three month period. The baseline demographic and clinical characteristics were comparable between both groups. At the end of three months, the Tellurium Metallicum group demonstrated a statistically significant mean improvement in the Dermatology Life Quality Index score, with a reduction of 8.80 compared to a minimal reduction of 2.5 in the placebo group. A responder analysis further revealed that every single patient in the homoeopathy group achieved a clinically meaningful improvement, which was defined as a score reduction of five or more points. In contrast, zero patients in the placebo group reached this threshold. There were no adverse events reported during the study period, indicating the treatment was safe and well tolerated. In conclusion, Tellurium Metallicum 30 Centesimal was significantly more effective than a placebo in improving the dermatology related quality of life for patients with Tinea corporis. This abstract contains the gist of the entire work within 300 words and avoids any abbreviated forms, references, or taxonomic authorities.